Next Article in Journal
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Next Article in Special Issue
Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
Previous Article in Journal
Regulation of Constitutive Interferon-Stimulated Genes (Isgs) in Tumor Cells Contributes to Enhanced Antitumor Response of Newcastle Disease Virus-Infected Tumor Vaccines
Previous Article in Special Issue
Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
Review

Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations

1
Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Received: 21 April 2018 / Revised: 23 May 2018 / Accepted: 4 June 2018 / Published: 6 June 2018
(This article belongs to the Special Issue Treatment of Older Adults with Acute Myeloid Leukemia)
Acute myeloid leukemia (AML) is a debilitating and life-threatening condition, especially for elderly patients who account for over 50% of diagnoses. For over four decades, standard induction therapy with intensive cytotoxic chemotherapy for AML had remained unchanged. However, for most patients, standard therapy continues to have its shortcomings, especially for elderly patients who may not be able to tolerate the complications from intensive cytotoxic chemotherapy. New research into the development of targeted and alternative therapies has led to a new era in AML therapy. For the nearly 20% of diagnoses harboring a mutation in isocitrate dehydrogenase 1 or 2 (IDH1/2), potential treatment options have undergone a paradigm shift away from intensive cytotoxic chemotherapy and towards targeted therapy alone or in combination with lower intensity chemotherapy. The first FDA approved IDH2 inhibitor was enasidenib in 2017. In addition, IDH1 inhibitors are in ongoing clinical studies, and the oral BCL-2 inhibitor venetoclax shows preliminary efficacy in this subset of patients. These new tools aim to improve outcomes and change the treatment paradigm for elderly patients with IDH mutant AML. However, the challenge of how to best incorporate these agents into standard practice remains. View Full-Text
Keywords: acute myeloid leukemia; treatment; elderly; enasidenib; AG-221; ivosidenib; AG-120; venetoclax; ABT-199 acute myeloid leukemia; treatment; elderly; enasidenib; AG-221; ivosidenib; AG-120; venetoclax; ABT-199
Show Figures

Figure 1

MDPI and ACS Style

Buege, M.J.; DiPippo, A.J.; DiNardo, C.D. Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations. Cancers 2018, 10, 187. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10060187

AMA Style

Buege MJ, DiPippo AJ, DiNardo CD. Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations. Cancers. 2018; 10(6):187. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10060187

Chicago/Turabian Style

Buege, Michael J., Adam J. DiPippo, and Courtney D. DiNardo 2018. "Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations" Cancers 10, no. 6: 187. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10060187

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop